Why hip cartilage damage is hard to treat without intervention

If your consultant has told you that you have cartilage damage in your hip, your first question is likely whether an injection — rather than an operation — is a realistic option. For carefully selected patients with the right type of damage, the answer is now yes: two minimally invasive routes are available privately in the UK, and understanding why cartilage needs external help makes it easier to see what each one is trying to do.

The articular cartilage that lines the ball and socket of the hip joint is hyaline cartilage — a dense, load-bearing tissue with no blood supply and no nerve fibres of its own. Because it has no circulation, it cannot recruit the repair cells that heal bone or skin after injury. Once a localised area of hyaline cartilage breaks down to exposed bone (Grade III or IV on clinical grading scales), the damage does not naturally reverse.

There is an important distinction worth holding in mind: a focal defect — a discrete patch of damage with healthy cartilage around it — is a different problem from diffuse osteoarthritis affecting the whole joint surface. Focal damage may be amenable to biological repair; widespread joint-wide arthritis is generally not, and total hip replacement remains the appropriate pathway at that stage.

The two treatments discussed in the sections that follow — a ChondroFiller injection and stem cell-based approaches — both aim to address earlier-stage hip cartilage loss, but they work through different mechanisms and suit different patient profiles.

ChondroFiller injection: how it works and what the hip evidence shows

At a ChondroFiller injection appointment, a clinician places the treatment directly into the hip joint during a standard outpatient visit — under ultrasound guidance, using local anaesthesia, with no operating theatre or general anaesthetic involved. The entire procedure avoids surgery.

What is injected is an acellular Type I collagen hydrogel: no cells are harvested from the patient, and nothing is grown in a laboratory. Once inside the joint, the scaffold gels in situ within minutes and settles over the focal cartilage defect. Over the following weeks and months, the patient's own progenitor cells migrate into the three-dimensional collagen matrix — a process called matrix-induced chondrogenesis — and begin depositing new cartilage-like tissue. Ex vivo work confirms active cell recruitment into the scaffold within the first two weeks of contact. The repair process continues for approximately 24 months. ChondroFiller holds CE-marked Class III medical device status.

The strongest hip-specific published evidence comes from a prospective cohort by Mazek (2021, PMC8460160), which examined 26 patients with acetabular cartilage lesions greater than 2 cm² treated with ChondroFiller gel. At three to five years, 17 of 21 patients available for follow-up — 81% — achieved good or excellent outcomes, and the pre- to post-treatment MRI difference was statistically significant. It is worth noting that this trial evidence base used arthroscopic delivery; the current outpatient injection pathway builds on the same biological principles but delivers the scaffold without surgery.

Across the broader ChondroFiller evidence base, published data report 70–85% of carefully selected patients achieving meaningful symptom relief at three to five years, with a mean Harris Hip Score improvement of approximately 33 points and MOCART MRI scores in the range of 70–87.

One selection boundary deserves plain emphasis: patients with pre-existing Tönnis Grade 2–3 osteoarthritis consistently showed poor results in the Mazek cohort. This is a meaningful eligibility filter, not a minor caveat — ChondroFiller injection is suited to focal, contained hip cartilage defects with healthy surrounding borders, not to generalised joint-wide arthritis.

Stem cell therapy for hip cartilage: UK trials and the NHS position

Stem cell therapy for hip cartilage is a genuine area of UK clinical investigation, not a fringe concept. The most credible domestic evidence comes from the HOAST trial — Hip Osteoarthritis treatment using Autologous Stem cell Therapy — sponsored by Oxford University and conducted at the Nuffield Orthopaedic Centre. HOAST was a world-first UK pilot RCT (40 patients) comparing hip arthroscopy with microfracture alone against the same procedure augmented with autologous bone marrow stem cells, in adults aged 18–75 with early hip OA. The goal was to establish whether the stem cells would encourage new hyaline cartilage rather than scar tissue, and potentially delay total hip replacement. The trial is now listed as completed, though results are not yet publicly available as of mid-2026; its pilot scale means any conclusions that do emerge will need replication before they can inform routine practice.

Beyond HOAST, a 2023 systematic review of mesenchymal stem cell (MSC) clinical trials found that intra-articular injections reduced pain and showed some cartilage signal on imaging, but were likely insufficient for full articular repair. The safety profile across published MSC trials is broadly reassuring — adverse events have generally been minor.

Despite this research activity, NHS England's patient decision aid for hip osteoarthritis states plainly that there is no good evidence stem cell therapy helps with hip pain. NICE and the British Orthopaedic Association have reached the same conclusion: current evidence is insufficient to recommend stem cell treatment for hip cartilage routinely, and the NHS does not fund it outside clinical trials. Private clinics — including centres in the north of England such as the Manchester Hip Clinic — offer bone marrow concentrate and adipose-derived cell injections, but these remain self-funded and outside any NHS-endorsed pathway, for now.

Which patients suit which treatment

Matching the right treatment to the right patient comes down to where on the disease spectrum the damage sits — focal and contained, early widespread, or advanced and diffuse. ChondroFiller injection and stem cell approaches are designed for different points on that spectrum, and understanding the distinction is the first step in any assessment.

ChondroFiller injection may suit patients who have:

• An isolated focal Grade III or IV hip cartilage defect with intact, healthy surrounding borders
• No significant underlying osteoarthritis — the Tönnis Grade boundary covered in the previous section is the key eligibility filter; readers who have already absorbed that detail do not need it restated here
• A defect broadly up to 3–6 cm² in area, confirmed on pre-treatment MRI

Age alone is not a hard disqualifier. The condition of the surrounding hip joint — including the opposing cartilage surface and the degree of any pre-existing OA — matters considerably more than the patient's age at the time of treatment.

Stem cell therapy trials have targeted patients who have:

• Early hip osteoarthritis as the primary diagnosis, rather than a single contained focal defect
• Sufficient remaining joint space to benefit from biological augmentation alongside a marrow-stimulation procedure, as in the HOAST trial's design for adults aged 18–75

This is a meaningfully different disease stage from the focal-defect profile that ChondroFiller injection addresses.

Neither treatment is appropriate for end-stage, diffuse hip arthritis affecting the whole joint surface. At that point, total hip replacement is the correct clinical pathway, and biological repair options are unlikely to offer realistic benefit.

For patients whose damage does fall within the biological repair range, ACI and MACI remain NHS-commissioned surgical alternatives at select UK centres — useful reference points for anyone weighing a two-stage, cell-based theatre procedure against a single outpatient injectable approach.

Pre-treatment MRI is essential for both pathways to confirm defect size, boundary integrity, and the overall health of the hip joint. A consultant assessment is the practical next step.

Cost, NHS funding, and how to access both treatments in the UK

Both ChondroFiller injection and stem cell therapy for hip cartilage are self-funded, private treatments — neither is commissioned by the NHS for hip cartilage repair outside an approved clinical trial.

ChondroFiller injection is available from approximately £3,000 for the outpatient ultrasound-guided pathway at a single lesion (London Cartilage Clinic, the first UK provider to offer it in this form); costs at other centres run from £3,800 to £9,500 depending on the scope of assessment and whether supplementary procedures are involved. Prices vary between providers, so patients should confirm current figures directly with the clinic.

Stem cell therapy for hip cartilage — whether bone marrow concentrate (BMAC) or adipose-derived cell injection — typically runs to several thousand pounds at UK private centres and may exceed £10,000 depending on technique and provider. Like ChondroFiller, it is available only on a self-pay basis outside approved trial settings.

Private medical insurance (PMI) does not routinely cover either treatment given their non-commissioned status. Patients should check with their insurer before assuming any contribution will apply.

For those seeking an NHS route, autologous chondrocyte implantation (ACI) remains the commissioned two-stage, cell-based surgical option at selected UK centres, including University Hospital Southampton. ACI involves a biopsy, a laboratory growth phase, and reimplantation — a more resource-intensive pathway, but one that sits within NHS coverage for eligible patients.

Patients who want to be assessed without waiting for a GP referral can self-refer directly. Lincolnshire Hip is part of the MSK Doctors group and accepts patients without a referral for hip assessment, including MRI review and treatment planning, with clinics in Sleaford and Grantham serving the wider Lincolnshire and East Midlands catchment.

What the evidence gap means when choosing between them

Evidence maturity varies between these two treatments — and for a patient making a decision in mid-2026, that gap has a practical shape.

For the hip joint specifically, ChondroFiller injection currently has the stronger published foundation: a prospective cohort with up to five years of follow-up, a defined Tönnis grade boundary that predicts poor outcomes, a safety record of over 19,000 cases without serious complication, and outcome measures — Harris Hip Score, MOCART — anchored to published data rather than extrapolated from other joints. The selection criteria are explicit enough that an imaging report and a consultant review can determine fairly quickly whether a patient falls within or outside the treatment's scope.

Stem cell therapy carries credible biological reasoning and the HOAST pilot RCT represents meaningful UK-specific work, but the large-trial, long-term hip data that would allow a like-for-like comparison with the ChondroFiller injection evidence base has not yet been published. HOAST's full results, when disseminated, will be the most relevant UK signal for the stem cell arm.

Critically, this asymmetry rarely forces a direct choice: the two approaches address different disease stages, so most patients are self-selecting into one pathway or the other before the question of relative evidence quality arises.

For anyone who does not fit either profile — too much diffuse joint involvement for focal scaffold repair, not eligible for a trial, not yet at the point of hip replacement — osteotomy, biologic injection support, and other conservative joint preservation measures remain on the table and worth raising at consultation.

The most useful questions to bring to that assessment are practical ones: what grade is the cartilage defect on MRI, what is the Tönnis grade of the surrounding joint, and does the imaging support focal repair or suggest a different pathway? Uncertainty about treatments is a reason to ask those questions precisely — not a reason to defer the conversation.